| Year |
Citation |
Score |
| 2023 |
Hercun J, Heller T, Glenn JS, Kleiner DE, Koh C. Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy. Frontiers in Medicine. 10: 1082069. PMID 37089591 DOI: 10.3389/fmed.2023.1082069 |
0.315 |
|
| 2023 |
Etzion O, Hamid S, Lurie Y, Gane EJ, Yardeni D, Duehren S, Bader N, Nevo-Shor A, Channa SM, Cotler SJ, Mawani M, Parkash O, Dahari H, Ingrid C, Glenn J. Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial. Hepatology (Baltimore, Md.). PMID 36800850 DOI: 10.1097/HEP.0000000000000309 |
0.348 |
|
| 2022 |
Mhlanga A, Zakh R, Churkin A, Reinharz V, Glenn JS, Etzion O, Cotler SJ, Yurdaydin C, Barash D, Dahari H. Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients. Mathematics (Basel, Switzerland). 10. PMID 36540372 DOI: 10.3390/math10203917 |
0.358 |
|
| 2022 |
Hassanein T, Tai D, Liu C, Box TD, Tong MJ, Rossaro L, Pozza R, Glenn JS, Cheung R, Hemaidan A, He Y, Behling C, Hu X, Makhlouf H, Fan H, et al. Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial. Evidence-Based Complementary and Alternative Medicine : Ecam. 2022: 4494099. PMID 35873630 DOI: 10.1155/2022/4494099 |
0.366 |
|
| 2021 |
Hercun J, Kim GE, Da BL, Rotman Y, Kleiner DE, Chang R, Glenn JS, Hoofnagle JH, Koh C, Heller T. Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy. Alimentary Pharmacology & Therapeutics. PMID 34048594 DOI: 10.1111/apt.16408 |
0.317 |
|
| 2020 |
Dinnon KH, Leist SR, Schäfer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL, Hou YJ, Adams LE, Gully KL, Brown AJ, Huang E, Bryant MD, Choong IC, ... Glenn JS, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. PMID 32854108 DOI: 10.1038/S41586-020-2708-8 |
0.323 |
|
| 2020 |
Fong TL, Lee BT, Chang M, Nasanbayar K, Tsogtoo E, Boldbaatar D, Dashdorj ED, Clifford NE, Dashdorj AN, Bang BR, Chida T, Lim C, Sugiyama M, Mizokami M, Dashdorj NJ, ... ... Glenn JS, et al. High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California. Digestive Diseases and Sciences. PMID 32770488 DOI: 10.1007/S10620-020-06499-6 |
0.456 |
|
| 2020 |
Cho NJ, Glenn JS. Materials science approaches in the development of broad-spectrum antiviral therapies. Nature Materials. PMID 32427958 DOI: 10.1038/S41563-020-0698-4 |
0.306 |
|
| 2020 |
Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS, Hartmann R, Kotenko SV, Lazear HM, O'Brien TR, Odendall C, Onabajo OO, Piontkivska H, Santer DM, Reich NC, Wack A, et al. COVID-19 and emerging viral infections: The case for interferon lambda. The Journal of Experimental Medicine. 217. PMID 32289152 DOI: 10.1084/Jem.20200653 |
0.349 |
|
| 2019 |
Liu HL, Lv J, Zhao ZM, Xiong AM, Tan Y, Glenn JS, Tao YY, Weng HL, Liu CH. Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis. Scientific Reports. 9: 18719. PMID 31822697 DOI: 10.1038/S41598-019-54663-4 |
0.325 |
|
| 2019 |
Koh C, Da BL, Glenn JS. HBV/HDV Coinfection: A Challenge for Therapeutics. Clinics in Liver Disease. 23: 557-572. PMID 31266627 DOI: 10.1016/J.Cld.2019.04.005 |
0.478 |
|
| 2019 |
Kim D, Adejumo AC, Yoo ER, Iqbal U, Li AA, Pham EA, Cholankeril G, Glenn JS, Ahmed A. Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017. Gastroenterology. PMID 31251928 DOI: 10.1053/J.Gastro.2019.06.026 |
0.304 |
|
| 2019 |
Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, et al. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. Journal of Hepatology. 70: 1008-1015. PMID 30982526 DOI: 10.1016/J.Jhep.2018.12.022 |
0.411 |
|
| 2019 |
Tsuge M, Uchida T, Walsh K, Ishida Y, Tateno C, Kumar U, Glenn JS, Koh C, Heller T, Uprichard SL, Dahari H, Chayama K. Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection. Viruses. 11. PMID 30875937 DOI: 10.3390/V11030263 |
0.381 |
|
| 2019 |
Townsend EC, Zhang GY, Ali R, Firke M, Moon MS, Han MAT, Fram B, Glenn JS, Kleiner DE, Koh C, Heller T. The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. Journal of Gastroenterology and Hepatology. PMID 30695096 DOI: 10.1111/Jgh.14617 |
0.433 |
|
| 2019 |
Mahale P, Aka P, Chen X, Pfeiffer RM, Liu P, Groover S, Mendy M, Njie R, Goedert JJ, Kirk GD, Glenn JS, O'Brien TR. Hepatitis D virus infection, cirrhosis, and hepatocellular carcinoma in The Gambia. Journal of Viral Hepatitis. PMID 30661282 DOI: 10.1111/Jvh.13065 |
0.399 |
|
| 2019 |
Etzion O, Hamid SS, Lurie Y, Gane E, Bader N, Yardeni D, Nevo-Shor a, channa s, Mawani M, Parkash O, Yang K, Longo D, Gish RG, Glenn J, Apelian D. PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection Journal of Hepatology. 70. DOI: 10.1016/S0618-8278(19)30058-1 |
0.431 |
|
| 2018 |
Koh C, Heller T, Glenn JS. Pathogenesis of and New Therapies for Hepatitis D. Gastroenterology. PMID 30342879 DOI: 10.1053/J.Gastro.2018.09.058 |
0.418 |
|
| 2018 |
Ng SS, Saeb-Parsy K, Blackford SJI, Segal JM, Serra MP, Horcas-Lopez M, No DY, Mastoridis S, Jassem W, Frank CW, Cho NJ, Nakauchi H, Glenn JS, Rashid ST. Human iPS derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold. Biomaterials. 182: 299-311. PMID 30149262 DOI: 10.1016/J.Biomaterials.2018.07.043 |
0.365 |
|
| 2018 |
Kim D, Li AA, Perumpail BJ, Gadiparthi C, Kim W, Cholankeril G, Glenn JS, Harrison SA, Younossi ZM, Ahmed A. Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. Hepatology (Baltimore, Md.). PMID 30014489 DOI: 10.1002/Hep.30161 |
0.306 |
|
| 2018 |
Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, Ahmed A. Changing Trends in Etiology-based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology. PMID 30009816 DOI: 10.1053/J.Gastro.2018.07.008 |
0.372 |
|
| 2018 |
Wang Y, Glenn JS, Winters MA, Shen LP, Choong I, Shi YL, Bi SL, Ma LY, Zeng H, Zhang FJ. A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection. Diagnostic Microbiology and Infectious Disease. PMID 29941366 DOI: 10.1016/J.Diagmicrobio.2018.05.016 |
0.34 |
|
| 2018 |
Mahale P, Aka PV, Chen X, Liu P, Fram BJ, Wang AS, Simenel S, Tseng FC, Chen S, Edlin BR, Glenn JS, O'Brien TR. Hepatitis D Viremia Among Injection Drug Users in San Francisco. The Journal of Infectious Diseases. 217: 1902-1906. PMID 29800369 DOI: 10.1093/Infdis/Jiy157 |
0.432 |
|
| 2018 |
Glenn JS. Emerging Therapeutic Targets for Hepatitis Delta Virus Infection. Gastroenterology & Hepatology. 14: 47-49. PMID 29491762 |
0.337 |
|
| 2017 |
Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H. Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatology Communications. 1: 288-292. PMID 29404459 DOI: 10.1002/hep4.1043 |
0.323 |
|
| 2017 |
Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, et al. Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop. Antiviral Research. PMID 29248746 DOI: 10.1016/J.Antiviral.2017.12.006 |
0.334 |
|
| 2017 |
Mahale P, Glenn JS, O'Brien TR. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus. Annals of Internal Medicine. 167: 759-760. PMID 29159388 DOI: 10.7326/L17-0476 |
0.46 |
|
| 2017 |
Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, Karatayli S, Bozdayi AM, Koh C, Heller T, Idilman R, Glenn JS. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The lowr HDV - 1 study. Hepatology (Baltimore, Md.). PMID 29152762 DOI: 10.1002/Hep.29658 |
0.338 |
|
| 2017 |
Alter H, Block TM, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Chisari FV, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten T, Guo H, et al. A Research Agenda for Curing Chronic Hepatitis B Virus Infection. Hepatology (Baltimore, Md.). PMID 28877549 DOI: 10.1002/Hep.29509 |
0.412 |
|
| 2017 |
Kim SO, Jackman JA, Elazar M, Cho SJ, Glenn JS, Cho NJ. Quantitative Evaluation of Viral Protein Binding to Phosphoinositide Receptors and Pharmacological Inhibition. Analytical Chemistry. PMID 28809547 DOI: 10.1021/Acs.Analchem.7B01568 |
0.319 |
|
| 2017 |
Elazar M, Koh C, Glenn JS. Hepatitis delta infection - Current and new treatment options. Best Practice & Research. Clinical Gastroenterology. 31: 321-327. PMID 28774414 DOI: 10.1016/J.Bpg.2017.05.001 |
0.439 |
|
| 2017 |
Ng SS, Xiong A, Nguyen K, Masek M, No DY, Elazar M, Shteyer E, Winters MA, Voedisch A, Shaw K, Rashid ST, Frank CW, Cho NJ, Glenn JS. Long-term culture of human liver tissue with advanced hepatic functions. Jci Insight. 2. PMID 28570275 DOI: 10.1172/Jci.Insight.90853 |
0.389 |
|
| 2017 |
Elazar M, Glenn JS. Emerging concepts for the treatment of hepatitis delta. Current Opinion in Virology. 24: 55-59. PMID 28475945 DOI: 10.1016/J.Coviro.2017.04.004 |
0.462 |
|
| 2017 |
Wedemeyer H, Port K, Deterding K, Wranke A, Kirschner J, Bruno B, Martins B, Glenn JS, Kornberg M, Manns MP. A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study Journal of Hepatology. 66. DOI: 10.1016/S0168-8278(17)30310-0 |
0.323 |
|
| 2017 |
Martins EB, Glenn J. Prevalence of Hepatitis Delta Virus (HDV) Infection in the United States: Results from an ICD-10 Review Gastroenterology. 152. DOI: 10.1016/S0016-5085(17)33657-0 |
0.396 |
|
| 2016 |
Wang Y, Lee JH, Shirahama H, Seo J, Glenn JS, Cho NJ. Extracellular Matrix Functionalization and Huh-7.5 Cell Coculture Promote the Hepatic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells in a 3D ICC Hydrogel Scaffold. Acs Biomaterials Science & Engineering. 2: 2255-2265. PMID 33465898 DOI: 10.1021/Acsbiomaterials.6B00487 |
0.328 |
|
| 2016 |
Pham EA, Perumpail RB, Fram BJ, Glenn JS, Ahmed A, Gish RG. Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Current Hepatology Reports. 15: 237-244. PMID 27917363 DOI: 10.1007/S11901-016-0315-9 |
0.436 |
|
| 2016 |
Chen X, Oidovsambuu O, Liu P, Grosely R, Elazar M, Winn VD, Fram B, Boa Z, Dai H, Dashtseren B, Yagaanbuyant D, Genden Z, Dashdorj N, Bungert A, Dashdorj N, ... Glenn JS, et al. A novel quantitative microarray antibody capture (Q-MAC) assay identifies an extremely high HDV prevalence amongst HBV infected Mongolians. Hepatology (Baltimore, Md.). PMID 27880976 DOI: 10.1002/Hep.28957 |
0.393 |
|
| 2016 |
Cho NJ, Pham EA, Hagey RJ, Lévêque VJ, Ma H, Klumpp K, Glenn JS. Reconstitution and Functional Analysis of a Full-Length Hepatitis C Virus NS5B Polymerase on a Supported Lipid Bilayer. Acs Central Science. 2: 456-66. PMID 27504492 DOI: 10.1021/Acscentsci.6B00112 |
0.436 |
|
| 2016 |
Deans RM, Morgens DW, Ökesli A, Pillay S, Horlbeck MA, Kampmann M, Gilbert LA, Li A, Mateo R, Smith M, Glenn JS, Carette JE, Khosla C, Bassik MC. Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Nature Chemical Biology. PMID 27018887 DOI: 10.1038/Nchembio.2050 |
0.348 |
|
| 2016 |
Rutaganira FU, Fowler ML, McPhail JA, Gelman MA, Nguyen K, Xiong A, Dornan GL, Tavshanjian B, Glenn JS, Shokat KM, Burke JE. Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ. Journal of Medicinal Chemistry. 59: 1830-9. PMID 26885694 DOI: 10.1021/Acs.Jmedchem.5B01311 |
0.666 |
|
| 2015 |
Xue MM, Glenn JS, Leung DH. Hepatitis D in Children. Journal of Pediatric Gastroenterology and Nutrition. 63: 271-281. PMID 26465797 DOI: 10.1097/Mpg.0000000000000998 |
0.42 |
|
| 2015 |
Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, ... ... Glenn JS, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. The Lancet. Infectious Diseases. PMID 26189433 DOI: 10.1016/S1473-3099(15)00074-2 |
0.436 |
|
| 2015 |
Xue MM, Glenn JS, Leung DH. Invited Review: Hepatitis D in Children. Journal of Pediatric Gastroenterology and Nutrition. PMID 25988557 DOI: 10.1097/MPG.0000000000000859 |
0.374 |
|
| 2015 |
Perumpail RB, Wong RJ, Ha LD, Pham EA, Wang U, Luong H, Kumari R, Daugherty TJ, Higgins JP, Younossi ZM, Kim WR, Glenn JS, Ahmed A. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transplant Infectious Disease : An Official Journal of the Transplantation Society. 17: 275-8. PMID 25641426 DOI: 10.1111/Tid.12348 |
0.346 |
|
| 2015 |
Cho NJ, Lee C, Pang PS, Pham EA, Fram B, Nguyen K, Xiong A, Sklan EH, Elazar M, Koytak ES, Kersten C, Kanazawa KK, Frank CW, Glenn JS. Phosphatidylinositol 4,5-bisphosphate is an HCV NS5A ligand and mediates replication of the viral genome. Gastroenterology. 148: 616-25. PMID 25479136 DOI: 10.1053/J.Gastro.2014.11.043 |
0.448 |
|
| 2015 |
David N, Yaffe Y, Hagoel L, Elazar M, Glenn JS, Hirschberg K, Sklan EH. The interaction between the hepatitis C proteins NS4B and NS5A is involved in viral replication. Virology. 475: 139-49. PMID 25462354 DOI: 10.1016/J.Virol.2014.10.021 |
0.413 |
|
| 2015 |
Perumpail RB, Liang R, McKinney JE, Kumari R, Lutchman G, Daugherty T, Nguyen MH, Glenn J, Cheung RC, Garcia G, Gregory PB, Kim WR, Ahmed A. Tu1041 Experience With Sofosbuvir-Based Antiviral Therapy in Septuagenarians and Octogenarians Gastroenterology. 148. DOI: 10.1016/S0016-5085(15)33730-6 |
0.424 |
|
| 2015 |
Koh C, Canini L, Dahari H, Cooper S, Cory D, Winters MA, Choong I, Cotler SJ, Kleiner DE, Yurdaydin C, Heller T, Glenn JS. Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection Journal of Clinical Virology. 69: 247. DOI: 10.1016/J.Jcv.2015.06.071 |
0.424 |
|
| 2014 |
Elazar M, Glenn JS. HCV NS5A inhibitors: the devil is in the details. Gastroenterology. 147: 273-7. PMID 24976028 DOI: 10.1053/J.Gastro.2014.06.021 |
0.403 |
|
| 2014 |
Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo YY, Masek M, Michie SA, Glenn J, Peltz G. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. Plos Medicine. 11: e1001628. PMID 24736310 DOI: 10.1371/Journal.Pmed.1001628 |
0.31 |
|
| 2014 |
Hassanein T, Box TD, Tong MJ, Pozza R, Rossaro L, Glenn J, Cheung RC, Hemaidan A, He Y, Sheng Y, Barakat F, Behling C, Liu C, Liu P, Vierling JM. Sa1319 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis (S-USIIT-01) Gastroenterology. 146. DOI: 10.1016/S0016-5085(14)60921-5 |
0.369 |
|
| 2013 |
Lasheen DS, Ismail MA, Abou El Ella DA, Ismail NS, Eid S, Vleck S, Glenn JS, Watts AG, Abouzid KA. Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity. Bioorganic & Medicinal Chemistry. 21: 2742-55. PMID 23583031 DOI: 10.1016/J.Bmc.2013.03.017 |
0.414 |
|
| 2013 |
Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, Winters MA, Proudfoot J, Glenn JS. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. Journal of Gastroenterology and Hepatology. 28: 1521-5. PMID 23574043 DOI: 10.1111/Jgh.12217 |
0.458 |
|
| 2013 |
Lisowski L, Elazar M, Chu K, Glenn JS, Kay MA. The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. Nucleic Acids Research. 41: 3688-98. PMID 23396439 DOI: 10.1093/Nar/Gkt068 |
0.448 |
|
| 2013 |
Nishimura T, Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, Liu M, Idilman R, Yurdaydin C, Angus P, Stedman C, Murphy B, Glenn J, Nakamura M, et al. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. The Journal of Pharmacology and Experimental Therapeutics. 344: 388-96. PMID 23143674 DOI: 10.1124/Jpet.112.198697 |
0.318 |
|
| 2012 |
Pang PS, Pham EA, Elazar M, Patel SG, Eckart MR, Glenn JS. Structural map of a microRNA-122: hepatitis C virus complex. Journal of Virology. 86: 1250-4. PMID 22072754 DOI: 10.1128/Jvi.06367-11 |
0.388 |
|
| 2011 |
Pang PS, Elazar M, Pham EA, Glenn JS. Simplified RNA secondary structure mapping by automation of SHAPE data analysis. Nucleic Acids Research. 39: e151. PMID 21965531 DOI: 10.1093/Nar/Gkr773 |
0.392 |
|
| 2011 |
Lee C, Ma H, Hang JQ, Leveque V, Sklan EH, Elazar M, Klumpp K, Glenn JS. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology. 414: 10-8. PMID 21513964 DOI: 10.1016/J.Virol.2011.03.026 |
0.497 |
|
| 2011 |
Gelman MA, Glenn JS. Mixing the right hepatitis C inhibitor cocktail. Trends in Molecular Medicine. 17: 34-46. PMID 21106440 DOI: 10.1016/J.Molmed.2010.10.005 |
0.45 |
|
| 2011 |
Matto M, Sklan EH, David N, Melamed-Book N, Casanova JE, Glenn JS, Aroeti B. Role for ADP ribosylation factor 1 in the regulation of hepatitis C virus replication. Journal of Virology. 85: 946-56. PMID 21068255 DOI: 10.1128/Jvi.00753-10 |
0.475 |
|
| 2010 |
Dvory-Sobol H, Pang PS, Glenn JS. The Future of HCV Therapy: NS4B as an Antiviral Target. Viruses. 2: 2481-92. PMID 21157574 DOI: 10.3390/V2112481 |
0.505 |
|
| 2010 |
Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, Glenn JS, Kirk GD, Segev DL, Nelson KE, Marks M, Heller T, Golub ET. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. The Journal of Infectious Diseases. 202: 845-52. PMID 20701536 DOI: 10.1086/655808 |
0.423 |
|
| 2010 |
Einav S, Sobol HD, Gehrig E, Glenn JS. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. The Journal of Infectious Diseases. 202: 65-74. PMID 20486856 DOI: 10.1086/653080 |
0.465 |
|
| 2010 |
Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, Symons J, Furman PA. Development of novel therapies for hepatitis C. Antiviral Research. 86: 79-92. PMID 20417376 DOI: 10.1016/J.Antiviral.2010.02.003 |
0.455 |
|
| 2010 |
Cho NJ, Dvory-Sobol H, Lee C, Cho SJ, Bryson P, Masek M, Elazar M, Frank CW, Glenn JS. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Science Translational Medicine. 2: 15ra6. PMID 20371471 DOI: 10.1126/Scitranslmed.3000331 |
0.489 |
|
| 2010 |
Bryson PD, Cho NJ, Einav S, Lee C, Tai V, Bechtel J, Sivaraja M, Roberts C, Schmitz U, Glenn JS. A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. Antiviral Research. 87: 1-8. PMID 20363257 DOI: 10.1016/J.Antiviral.2010.03.013 |
0.49 |
|
| 2010 |
Lue J, Lin G, Ning H, Xiong A, Lin CS, Glenn JS. Transdifferentiation of adipose-derived stem cells into hepatocytes: a new approach. Liver International : Official Journal of the International Association For the Study of the Liver. 30: 913-22. PMID 20353420 DOI: 10.1111/J.1478-3231.2010.02231.X |
0.314 |
|
| 2010 |
Parameswaran P, Sklan E, Wilkins C, Burgon T, Samuel MA, Lu R, Ansel KM, Heissmeyer V, Einav S, Jackson W, Doukas T, Paranjape S, Polacek C, dos Santos FB, Jalili R, ... ... Glenn JS, et al. Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. Plos Pathogens. 6: e1000764. PMID 20169186 DOI: 10.1371/Journal.Ppat.1000764 |
0.36 |
|
| 2009 |
Cho NJ, Dvory-Sobol H, Xiong A, Cho SJ, Frank CW, Glenn JS. Mechanism of an amphipathic alpha-helical peptide's antiviral activity involves size-dependent virus particle lysis. Acs Chemical Biology. 4: 1061-7. PMID 19928982 DOI: 10.1021/Cb900149B |
0.415 |
|
| 2009 |
Pang PS, Kamal A, Glenn JS. The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society. 15: 1126-32. PMID 19718638 DOI: 10.1002/Lt.21835 |
0.347 |
|
| 2009 |
Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. Plos One. 4: e6579. PMID 19668364 DOI: 10.1371/Journal.Pone.0006579 |
0.433 |
|
| 2009 |
Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol JF, Glenn JS. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology. 137: 1827-35. PMID 19664635 DOI: 10.1053/J.Gastro.2009.07.056 |
0.467 |
|
| 2009 |
Sklan EH, Charuworn P, Pang PS, Glenn JS. Mechanisms of HCV survival in the host. Nature Reviews. Gastroenterology & Hepatology. 6: 217-27. PMID 19347013 DOI: 10.1038/Nrgastro.2009.32 |
0.448 |
|
| 2009 |
Cho NJ, Elazar M, Xiong A, Lee W, Chiao E, Baker J, Frank CW, Glenn JS. Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel. Biomedical Materials (Bristol, England). 4: 011001. PMID 18981544 DOI: 10.1088/1748-6041/25/1/011001 |
0.422 |
|
| 2009 |
Glenn J. New Targets within Hepatitis C Virus NS4B Antiviral Research. 82. DOI: 10.1016/J.Antiviral.2009.02.019 |
0.441 |
|
| 2008 |
Xiong A, Austin TW, Lagasse E, Uchida N, Tamaki S, Bordier BB, Weissman IL, Glenn JS, Millan MT. Isolation of human fetal liver progenitors and their enhanced proliferation by three-dimensional coculture with endothelial cells. Tissue Engineering. Part A. 14: 995-1006. PMID 19230124 DOI: 10.1089/Ten.Tea.2007.0087 |
0.313 |
|
| 2008 |
Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nature Biotechnology. 26: 1019-27. PMID 18758449 DOI: 10.1038/Nbt.1490 |
0.47 |
|
| 2008 |
Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrobial Agents and Chemotherapy. 52: 4069-71. PMID 18710916 DOI: 10.1128/Aac.00078-08 |
0.446 |
|
| 2008 |
Chiao E, Elazar M, Xing Y, Xiong A, Kmet M, Millan MT, Glenn JS, Wong WH, Baker J. Isolation and transcriptional profiling of purified hepatic cells derived from human embryonic stem cells. Stem Cells (Dayton, Ohio). 26: 2032-41. PMID 18535157 DOI: 10.1634/Stemcells.2007-0964 |
0.36 |
|
| 2008 |
Einav S, Sklan EH, Moon HM, Gehrig E, Liu P, Hao Y, Lowe AW, Glenn JS. The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection. Hepatology (Baltimore, Md.). 47: 827-35. PMID 18081150 DOI: 10.1002/Hep.22108 |
0.424 |
|
| 2007 |
Sklan EH, Serrano RL, Einav S, Pfeffer SR, Lambright DG, Glenn JS. TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication. The Journal of Biological Chemistry. 282: 36354-61. PMID 17901050 DOI: 10.1074/Jbc.M705221200 |
0.47 |
|
| 2007 |
Cho NJ, Cho SJ, Hardesty JO, Glenn JS, Frank CW. Creation of lipid partitions by deposition of amphipathic viral peptides. Langmuir : the Acs Journal of Surfaces and Colloids. 23: 10855-63. PMID 17803321 DOI: 10.1021/La700640H |
0.309 |
|
| 2007 |
Sklan EH, Staschke K, Oakes TM, Elazar M, Winters M, Aroeti B, Danieli T, Glenn JS. A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication. Journal of Virology. 81: 11096-105. PMID 17686842 DOI: 10.1128/Jvi.01249-07 |
0.474 |
|
| 2007 |
Cho NJ, Cheong KH, Lee C, Frank CW, Glenn JS. Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranes. Journal of Virology. 81: 6682-9. PMID 17428867 DOI: 10.1128/Jvi.02783-06 |
0.325 |
|
| 2006 |
Glenn JS. Prenylation of HDAg and antiviral drug development. Current Topics in Microbiology and Immunology. 307: 133-49. PMID 16903224 DOI: 10.1007/3-540-29802-9_7 |
0.443 |
|
| 2006 |
Glenn JS. Molecular virology of the hepatitis C virus: implication for novel therapies. Infectious Disease Clinics of North America. 20: 81-98. PMID 16527650 DOI: 10.1016/J.Idc.2006.01.001 |
0.446 |
|
| 2005 |
Glenn JS. Novel therapies for hepatitis C virus based on lessons from virology. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 3: S86-8. PMID 16234068 DOI: 10.1016/S1542-3565(05)00703-2 |
0.483 |
|
| 2005 |
Glenn JS. Molecular virology of the hepatitis C virus: implication for novel therapies. Clinics in Liver Disease. 9: 353-69, v. PMID 16023970 DOI: 10.1016/J.Cld.2005.05.013 |
0.456 |
|
| 2004 |
Matto M, Rice CM, Aroeti B, Glenn JS. Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts. Journal of Virology. 78: 12047-53. PMID 15479844 DOI: 10.1128/Jvi.78.21.12047-12053.2004 |
0.418 |
|
| 2004 |
Elazar M, Liu P, Rice CM, Glenn JS. An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. Journal of Virology. 78: 11393-400. PMID 15452261 DOI: 10.1128/Jvi.78.20.11393-11400.2004 |
0.461 |
|
| 2004 |
Einav S, Elazar M, Danieli T, Glenn JS. A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. Journal of Virology. 78: 11288-95. PMID 15452248 DOI: 10.1128/Jvi.78.20.11288-11295.2004 |
0.472 |
|
| 2004 |
Glenn JS. Overdependence on the host-an Achilles' heel of HCV? Hepatology (Baltimore, Md.). 39: 1734-5. PMID 15185316 DOI: 10.1002/Hep.20250 |
0.474 |
|
| 2004 |
Bordier BB, Glenn JS. Testing antivirals against hepatitis delta virus: farnesyl transferase inhibitors. Methods in Molecular Medicine. 96: 539-53. PMID 14762290 DOI: 10.1385/1-59259-670-3:539 |
0.466 |
|
| 2003 |
Einav S, Glenn JS. Prenylation inhibitors: a novel class of antiviral agents. The Journal of Antimicrobial Chemotherapy. 52: 883-6. PMID 14613953 DOI: 10.1093/Jac/Dkg490 |
0.447 |
|
| 2003 |
Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, Meuse L, Kay MA, Casey JL, Sebti SM, Hamilton AD, Glenn JS. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. The Journal of Clinical Investigation. 112: 407-14. PMID 12897208 DOI: 10.1172/Jci17704 |
0.483 |
|
| 2003 |
Elazar M, Cheong KH, Liu P, Greenberg HB, Rice CM, Glenn JS. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. Journal of Virology. 77: 6055-61. PMID 12719597 DOI: 10.1128/Jvi.77.10.6055-6061.2003 |
0.47 |
|
| 2002 |
Bordier BB, Marion PL, Ohashi K, Kay MA, Greenberg HB, Casey JL, Glenn JS. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. Journal of Virology. 76: 10465-72. PMID 12239323 DOI: 10.1128/Jvi.76.20.10465-10472.2002 |
0.454 |
|
| 2001 |
Cooper SL, Glenn JS, Greenberg HB. Host–microbe interactions: viruses Lessons in defense: hepatitis C, a case study Current Opinion in Microbiology. 4: 222. DOI: 10.1016/S1369-5274(00)00192-2 |
0.374 |
|
| 2000 |
Ohashi K, Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, Schwall R, Greenberg HB, Glenn JS, Kay MA. Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nature Medicine. 6: 327-31. PMID 10700236 DOI: 10.1038/73187 |
0.434 |
|
| 1998 |
Glenn JS, Marsters JC, Greenberg HB. Use of a prenylation inhibitor as a novel antiviral agent. Journal of Virology. 72: 9303-6. PMID 9765479 DOI: 10.1128/Jvi.72.11.9303-9306.1998 |
0.399 |
|
| 1998 |
Glenn JS, Marsters JC, Greenberg HB. The prenylation inhibitor BZA-5B prevents virus particle assembly Gastroenterology. 114. DOI: 10.1016/S0016-5085(98)85057-9 |
0.326 |
|
| 1993 |
Glenn JS, Ellens H, White JM. Delivery of liposome-encapsulated RNA to cells expressing influenza virus hemagglutinin. Methods in Enzymology. 221: 327-39. PMID 7689688 DOI: 10.1016/0076-6879(93)21028-7 |
0.369 |
|
| 1992 |
Glenn JS, Watson JA, Havel CM, White JM. Identification of a prenylation site in delta virus large antigen. Science (New York, N.Y.). 256: 1331-3. PMID 1598578 DOI: 10.1126/Science.1598578 |
0.374 |
|
| 1991 |
Glenn JS, White JM. trans-dominant inhibition of human hepatitis delta virus genome replication. Journal of Virology. 65: 2357-61. PMID 2016764 DOI: 10.1128/Jvi.65.5.2357-2361.1991 |
0.323 |
|
| 1990 |
Glenn JS, Taylor JM, White JM. In vitro-synthesized hepatitis delta virus RNA initiates genome replication in cultured cells. Journal of Virology. 64: 3104-7. PMID 2335830 DOI: 10.1128/Jvi.64.6.3104-3107.1990 |
0.406 |
|
| Show low-probability matches. |